Risk of relapse among non-lepromatous patients released from treatment after dapsone monotherapy.
Information on 14,625 non-lepromatous patients released from treatment after dapsone monotherapy and followed up to a maximum of 15 years at the ILEP project. Dharmapuri, India, was analysed to study the pattern of relapses. The overall relapse rate was 5/1000 person years. Males had a higher relapse rate than females. The risk of relapse increased with age, number of lesions and duration of treatment. The risk for relapse remained constant over several years after release from treatment. Even though the absolute risk for relapse after MDT may be different, the pattern of relapses and the factors affecting it may be similar to what has been shown in this study.
Pandian
T D
TD
DANLEP, Salem, India.
Muliyil
J
J
Vellut
C
C
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003622:Dapsone / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007918:Leprosy / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D012008:Recurrence; D012307:Risk Factors
D003622:Dapsone